Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism

University of Manitoba

Principal Investigator

Diabetes Research Group

John Buhler Research Centre

Winnipeg, Manitoba, Canada

Related Videos

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy? Video

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial? Video

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction? Video

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?